News & Views
Collaboration to Investigate Potential Antibody Candidates
May 14 2021
Global immunology company argenx has signed an agreement with FairJourney Biologics S.A (FJB) and IONTAS Limited (IONTAS) to explore diverse panels of novel antibody candidates within IONTAS’ proprietary mammalian display technology. The agreement includes provision of a dedicated full-time team assigned to the project.
Both companies have highly complementary capabilities for identification of potential next-generation antibody candidates, including argenx’s pipeline of investigational immunology therapies aimed at improving the lives of people living with severe autoimmune diseases and cancer. Through its Immunology Innovation Program, argenx collaborates with leading researchers to translate immunology breakthroughs in disease biology into differentiated therapeutic antibodies.
Dr António Parada, CEO at FairJourney Biologics and IONTAS commented: “We have gained considerable experience in antibody discovery through mammalian display for use in generating therapeutics with specific properties.
“Additionally, we continue to make improvements to the technology that will allow more diverse applications. We look forward to growing our relationship with argenx and applying our deep knowledge and experience to generate a diverse set of antibodies for potential immunological application.”
More information online
Digital Edition
International Labmate Buyers' Guide 2024/25
June 2024
Buyers' Guide featuring: Product Listings & Manufacturers Directory Chromatography Articles - Enhancing HPLC Field Service with fast-response, non-invasive flowmeters - Digital transformatio...
View all digital editions
Events
Jul 07 2024 Dublin, Ireland
Jul 20 2024 Denver, CO, USA
Jul 21 2024 Cape Town, South Africa
Jul 28 2024 San Diego, CA USA
Jul 30 2024 Jakarta, Indonesia